CN Patent

CN104650086A — 盐酸帕纳替尼化合物

Assigned to Tianjin Hankang Pharmaceutical Biotechnology Co Ltd · Expires 2015-05-27 · 11y expired

What this patent protects

本发明属于医药技术领域，具体涉及盐酸帕纳替尼晶体及其制备方法，本发明得到的盐酸帕纳替尼晶体具有的优点：纯度高；稳定性好，即使在高湿度条件下吸湿增重也不明显。本发明还涉及使用盐酸帕纳替尼晶体的组合物治疗白血病的应用。

USPTO Abstract

本发明属于医药技术领域，具体涉及盐酸帕纳替尼晶体及其制备方法，本发明得到的盐酸帕纳替尼晶体具有的优点：纯度高；稳定性好，即使在高湿度条件下吸湿增重也不明显。本发明还涉及使用盐酸帕纳替尼晶体的组合物治疗白血病的应用。

Drugs covered by this patent

ponatinib-hydrochloride (PONATINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN104650086A
Jurisdiction: CN
Classification: —
Expires: 2015-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Tianjin Hankang Pharmaceutical Biotechnology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.